Waterline Ventures

Robbie Greenglass leads investment decisions as the firm's founder and managing partner. His professional background includes investment banking at Goldman Sachs and operating experience within healthcare technology companies prior to launching Waterline. The firm operates with a concentrated decision-making structure typical of early-stage, thesis-driven venture firms.

Waterline focuses on Seed through Series B investments in healthcare technology and services companies. The firm often leads or co-leads rounds and positions itself as a first institutional check for founders building at the intersection of software and healthcare delivery. It does not invest in preclinical therapeutics, medical devices, or diagnostic hardware.

Despite its Cambridge, Massachusetts location — a global hub for biotech and life sciences — Waterline Ventures does not invest in therapeutics, drug discovery platforms, medical devices, or diagnostics. The firm draws a hard boundary around software and tech-enabled services, avoiding capital-intensive, clinical-trial-dependent business models entirely.

Waterline operates as a direct investor, writing equity checks into individual companies rather than committing capital to other venture funds. There is no public evidence the firm operates a fund-of-funds program or participates as a limited partner in external vehicles.

Deal flow derives from the firm's embedded position in the digital health ecosystem — relationships with health system innovation groups, payer executives, and a network of portfolio founders who have exited or scaled. Greenglass's dual background in finance and healthcare operations provides a referral surface that spans both the venture and provider communities.

Waterline Ventures operates as an asset manager — a venture capital firm raising discretionary institutional capital, not a single-family office. There is no public evidence the firm manages a single family's wealth or operates a multi-family office structure alongside its venture funds.

Per the firm's official communications, confirmed portfolio positions include Wellframe (acquired by Virgin Pulse), Firefly Health, and Qventus. The common thread across these positions is software applied to clinical workflow, care navigation, and hospital operations — a deliberate concentration rather than a broad health-tech sweep.